JOP20230218A1 - مشتقات بيرازولو بيريدين واستخداماتها - Google Patents

مشتقات بيرازولو بيريدين واستخداماتها

Info

Publication number
JOP20230218A1
JOP20230218A1 JOJO/P/2023/0218A JOP20230218A JOP20230218A1 JO P20230218 A1 JOP20230218 A1 JO P20230218A1 JO P20230218 A JOP20230218 A JO P20230218A JO P20230218 A1 JOP20230218 A1 JO P20230218A1
Authority
JO
Jordan
Prior art keywords
hemoglobinopathies
beta
expression
pyrazolopyridine derivatives
interneuron
Prior art date
Application number
JOJO/P/2023/0218A
Other languages
English (en)
Inventor
Andrew W Patterson
Rama Jain
Natalie Alysia Dales
Hasnain Ahmed Malik
James R Manning
Matthew James Hesse
Gary O'brien
Simone Bonazzi
Noel Marie-France Thomsen
Pamela Yf Ting
Janetta Dewhurst
Artiom Cernijenko
Jennifer Stroka Cobb
John Ryan Kerrigan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20230218A1 publication Critical patent/JOP20230218A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بالصيغة (I) وتركيبات صيدلانية واستخدامها في خفض مستويات التعبير عن محفزات إصبع زنك (WIZ) متباعدة بينياً على نطاق واسع، أو حث التعبير عن هيموجلوبين جنيني (HbF)، وفي معالجة اضطرابات الدم الموروثة (على سبيل المثال، اعتلالات الهيموجلوبين بالدم، على سبيل المثال، اعتلالات بيتا-هيموجلوبين بالدم)، مثل مرض خلية منجلية وبيتا-ثالاسيما.--
JOJO/P/2023/0218A 2021-03-15 2023-09-14 مشتقات بيرازولو بيريدين واستخداماتها JOP20230218A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161139P 2021-03-15 2021-03-15
US202163164130P 2021-03-22 2021-03-22
PCT/IB2022/052281 WO2022195454A1 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
JOP20230218A1 true JOP20230218A1 (ar) 2023-09-14

Family

ID=80819999

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0218A JOP20230218A1 (ar) 2021-03-15 2023-09-14 مشتقات بيرازولو بيريدين واستخداماتها

Country Status (20)

Country Link
US (4) US11787785B2 (ar)
EP (1) EP4308562A1 (ar)
JP (2) JP7659648B2 (ar)
KR (1) KR102902295B1 (ar)
AU (2) AU2022239950B2 (ar)
CA (1) CA3208951A1 (ar)
CL (1) CL2023002726A1 (ar)
CO (1) CO2023013486A2 (ar)
CR (1) CR20230486A (ar)
DO (1) DOP2023000188A (ar)
EC (1) ECSP23076800A (ar)
IL (1) IL305931A (ar)
JO (1) JOP20230218A1 (ar)
MX (1) MX2023010827A (ar)
PE (1) PE20242203A1 (ar)
PY (1) PY2217419A (ar)
TW (1) TWI923713B (ar)
UY (1) UY39671A (ar)
WO (1) WO2022195454A1 (ar)
ZA (1) ZA202307290B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021255160B2 (en) 2020-04-13 2024-02-01 Aptabio Therapeutics Inc. Pulmonary fibrosis medicine containing pyrazole derivative
EP4308559A1 (en) * 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
JP2020009513A (ja) * 2018-07-10 2020-01-16 キオクシア株式会社 メモリシステム
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4100394B1 (en) 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
US20230089530A1 (en) 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Also Published As

Publication number Publication date
PE20242203A1 (es) 2024-11-19
ZA202307290B (en) 2024-09-25
JP7659648B2 (ja) 2025-04-09
TW202304900A (zh) 2023-02-01
AU2022239950B2 (en) 2024-09-12
AU2022239950A1 (en) 2023-08-31
MX2023010827A (es) 2023-09-28
CL2023002726A1 (es) 2024-04-01
BR112023018542A2 (pt) 2023-10-10
EP4308562A1 (en) 2024-01-24
US20250282762A1 (en) 2025-09-11
JP2024509981A (ja) 2024-03-05
AU2024278210A1 (en) 2025-01-02
UY39671A (es) 2022-10-31
CA3208951A1 (en) 2022-09-22
AU2024278210B2 (en) 2026-03-26
DOP2023000188A (es) 2023-11-15
PY2217419A (es) 2022-09-27
WO2022195454A1 (en) 2022-09-22
NZ802195A (en) 2025-10-31
IL305931A (en) 2023-11-01
ECSP23076800A (es) 2023-11-30
KR102902295B1 (ko) 2025-12-23
US20250002479A1 (en) 2025-01-02
US20240158374A1 (en) 2024-05-16
US12172984B2 (en) 2024-12-24
CO2023013486A2 (es) 2023-11-10
KR20230156766A (ko) 2023-11-14
US11787785B2 (en) 2023-10-17
US12252482B2 (en) 2025-03-18
US20230108325A1 (en) 2023-04-06
TWI923713B (zh) 2026-05-01
CR20230486A (es) 2024-01-25
JP2025106341A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
JOP20220152A1 (ar) مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها
ZA202307290B (en) Pyrazolopyridine derivatives and uses thereof
JOP20230308A1 (ar) 3-(1-أوكسويزويندولين-2-ييل)بيبيريدين-2,6-مشتقات ديون واستخداماتها الطبية
JOP20250258A1 (ar) مثبطات 2-آزا باي سيكلو هبتان kras
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
PH12022553019A1 (en) Il-17a modulators
MX2022014925A (es) Moduladores de il-17a.
MX2025010350A (es) Composiciones y metodos para aumentar la hemoglobina fetal y tratar la anemia de celulas falciformes
MX2020012336A (es) Formulacion farmaceutica.
EP2886112A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF EYE DISEASES WITH S-ALLYL-L-CYSTEIN AS AN ACTIVE AND PHARMACEUTICAL FORMULATION THEREWITH
MX2025006619A (es) Compuestos terapeuticos
BR112017016278A2 (pt) agente preventivo e/ou terapêutico de doença imune
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
ZA202102412B (en) Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones
WO2022043273A3 (en) Oral care composition comprising a fructanase
CY1123360T1 (el) Ενωσεις oi οποιες εχουν αντιοξειδωτικη δραση εναντι των ελευθερων ριζων και αντιφλεγμονωδη δραση, και αντιστοιχες φαρμακευτικες συνθεσεις για τη φροντιδα του δερματος
FR2358893A1 (fr) Composition antimicrobienne contenant des 1-imidazolyl-butane-2-ones ou -butane-2-ols halogenes
GEAP202416397A (en) Topical formulations comprising benzoyl peroxide and azelaic acid, and use thereof
Queiroz et al. Report of two microabrasion techniques of enamel to remove stains and discussion
Roberts Tranexamic acid–A recipe for saving lives in traumatic bleeding
EA028540B1 (ru) Применение адсорбированного гомогената трутневого расплода и витамина dили витаминов группы d и/или их активных метаболитов для профилактики и лечения вирусных заболеваний
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
MX2025007516A (es) Compuesto de naftilamida y metodo de preparacion del mismo y uso del mismo
GEAP202416416A (en) Urea derivatives which can be used to treat cancer
Johar et al. Lasers Used in Dentistry